{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T21:22:41Z","timestamp":1783027361164,"version":"3.54.6"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cancer Policy"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jcpo.2026.100744","type":"journal-article","created":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T14:57:12Z","timestamp":1776524232000},"page":"100744","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The excessive, opportunistic price increase of generic oncology drug floxuridine"],"prefix":"10.1016","volume":"48","author":[{"given":"Parthay H","family":"Rokad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhaumik B.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umesh R.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcpo.2026.100744_bib1","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/1475-6773.13961","article-title":"Trends and determinants of retail prescription drug costs","volume":"57","author":"Teasdale","year":"2020","journal-title":"Health Serv. Res."},{"key":"10.1016\/j.jcpo.2026.100744_bib2","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/jlb\/lsw008","article-title":"Off-patent drugs at brand-name prices: a puzzle for policymakers","volume":"3","author":"Tallapragada","year":"2016","journal-title":"J. Law Biosci."},{"key":"10.1016\/j.jcpo.2026.100744_bib3","unstructured":"Fox 13 Tampa Bay, Florida drug supplier accused of price gouging cancer drug. \u3008https:\/\/www.fox13news.com\/news\/florida-drug-supplier-accused-of-price-gouging-cancer-drug\u3009, 2017 (accessed March 18, 2026)."},{"key":"10.1016\/j.jcpo.2026.100744_bib4","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases, LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, 2012. \u3008https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548421\/\u3009."},{"key":"10.1016\/j.jcpo.2026.100744_bib5","unstructured":"JND Therapeutics, Floxuridine For Injection, USP [product page]. \u3008https:\/\/www.jndtherapeutics.com\/product.html\u3009 (accessed June 23, 2025)."},{"key":"10.1016\/j.jcpo.2026.100744_bib6","unstructured":"Centers for Medicare & Medicaid Services, Medicare Part B Drug Average Sales Price (ASP) Pricing Files. \u3008https:\/\/www.cms.gov\/medicare\/payment\/part-b-drugs\/asp-pricing-files\u3009 (accessed June 23, 2025)."},{"key":"10.1016\/j.jcpo.2026.100744_bib7","unstructured":"Montana Department of Public Health and Human Services, July 2022 Physician Services Fee Schedule. \u3008https:\/\/medicaidprovider.mt.gov\/docs\/feeschedules\/2022FS\/July2022\/July2022PhysicianFeeScheduleREVISED09122022.pdf\u3009 (accessed June 23, 2025)."},{"key":"10.1016\/j.jcpo.2026.100744_bib8","unstructured":"Montana Department of Public Health and Human Services, July 2023 Physician Services Fee Schedule. \u3008https:\/\/medicaidprovider.mt.gov\/docs\/feeschedules\/2024\/July2023PhysicianServicesFeeScheduleV2.pdf\u3009 (accessed June 23, 2025)."},{"key":"10.1016\/j.jcpo.2026.100744_bib9","unstructured":"American Society of Health-System Pharmacists, Drug shortage detail: floxuridine injection. \u3008https:\/\/www.ashp.org\/drug-shortages\/current-shortages\/drug-shortage-detail.aspx?id=687\u3009 (accessed June 23, 2025)."},{"key":"10.1016\/j.jcpo.2026.100744_bib10","unstructured":"Excalibur Randomized Control Trial, New supplier of floxuridine. \u3008https:\/\/excaliburstudy.com\/new-supplier-of-floxuridine\/\u3009 (accessed June 23, 2025)."},{"key":"10.1016\/j.jcpo.2026.100744_bib11","unstructured":"U.S. Bureau of Labor Statistics, Consumer Price Index for All Urban Consumers (CPI-U). \u3008https:\/\/data.bls.gov\/timeseries\/CUUR0000SA0\u3009 (accessed June 29, 2025)."},{"key":"10.1016\/j.jcpo.2026.100744_bib12","unstructured":"U.S. Food and Drug Administration, Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. \u3008https:\/\/www.accessdata.fda.gov\/scripts\/cder\/ob\/index.cfm\u3009 (accessed June 23, 2025)."},{"key":"10.1016\/j.jcpo.2026.100744_bib13","unstructured":"U.S. Food and Drug Administration, Drugs@FDA: Floxuridine, ANDA 075387. \u3008https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=075387\u3009 (accessed June 23, 2025)."},{"key":"10.1016\/j.jcpo.2026.100744_bib14","unstructured":"Kaiser Family Foundation, Explaining the Prescription Drug Provisions in the Inflation Reduction Act. \u3008https:\/\/www.kff.org\/medicare\/issue-brief\/explaining-the-prescription-drug-provisions-in-the-inflation-reduction-act\/\u3009 (accessed June 23, 2025)."},{"key":"10.1016\/j.jcpo.2026.100744_bib15","unstructured":"National Cancer Institute, CanMED: NDC 00143-9270. \u3008https:\/\/seer.cancer.gov\/oncologytoolbox\/canmed\/ndconc\/00143-9270\/\u3009 (accessed June 23, 2025)."},{"key":"10.1016\/j.jcpo.2026.100744_bib16","unstructured":"National Cancer Institute, CanMED: NDC 81643-9270. \u3008https:\/\/seer.cancer.gov\/oncologytoolbox\/canmed\/ndconc\/81643-9270\/\u3009 (accessed June 23, 2025)."},{"key":"10.1016\/j.jcpo.2026.100744_bib17","unstructured":"Intera Oncology, Hepatic Artery Infusion (HAI) Therapy is Now Available in More than 65 Medical Centers. \u3008https:\/\/www.prweb.com\/releases\/hepatic-artery-infusion-hai-therapy-is-now-available-nationwide-in-more-than-65-medical-centers-302047864.html\u3009."},{"key":"10.1016\/j.jcpo.2026.100744_bib18","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/s12885-019-5515-6","article-title":"Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases - the multicenter randomized controlled PUMP trial","volume":"19","author":"Buisman","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jcpo.2026.100744_bib19","unstructured":"ECOG-ACRIN Cancer Research Group, Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Alone for Patients with Unresectable Colorectal Liver Metastases: The PUMP Trial. \u3008https:\/\/ecog-acrin.org\/clinical-trials\/ea2222-pump-colorectal-cancer\u3009 (accessed March 16, 2026)."},{"key":"10.1016\/j.jcpo.2026.100744_bib20","unstructured":"National Comprehensive Cancer Network (NCCN), Colon. \u3008https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/colon.pdf\u3009 (accessed March 16, 2026)."}],"container-title":["Journal of Cancer Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538326000457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538326000457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T20:51:36Z","timestamp":1783025496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213538326000457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":20,"alternative-id":["S2213538326000457"],"URL":"https:\/\/doi.org\/10.1016\/j.jcpo.2026.100744","relation":{},"ISSN":["2213-5383"],"issn-type":[{"value":"2213-5383","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The excessive, opportunistic price increase of generic oncology drug floxuridine","name":"articletitle","label":"Article Title"},{"value":"Journal of Cancer Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcpo.2026.100744","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100744"}}